Johnson & Johnson: Janssen Submits Application to U.S. FDA Seeking Approval of New DARZALEX Subcutaneous Formulation
July 12, 2019
July 12, 2019
RARITAN, New Jersey, July 12 -- Janssen Pharmaceutical Companies, a subsidiary of Johnson and Johnson, issued the following news release:
* * *
- Submission Inclusive of Data From Phase 3 COLUMBA Study Presented at ASCO
* * *
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of a new subcutaneous (S . . .
* * *
- Submission Inclusive of Data From Phase 3 COLUMBA Study Presented at ASCO
* * *
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of a new subcutaneous (S . . .